Insmed, Inc. (NASDAQ:INSM) Shares Acquired by Swiss National Bank

Swiss National Bank lifted its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 2.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 329,300 shares of the biopharmaceutical company's stock after acquiring an additional 8,200 shares during the quarter. Swiss National Bank owned 0.18% of Insmed worth $25,122,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in INSM. Cullen Frost Bankers Inc. grew its position in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the last quarter. Elequin Capital LP purchased a new stake in Insmed during the 4th quarter worth approximately $28,000. NBC Securities Inc. purchased a new stake in Insmed during the 1st quarter worth approximately $49,000. Versant Capital Management Inc grew its position in Insmed by 546.3% during the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 590 shares during the last quarter. Finally, Signaturefd LLC lifted its stake in Insmed by 60.0% during the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after acquiring an additional 325 shares during the period.

Insider Activity

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the sale, the insider owned 89,407 shares of the company's stock, valued at approximately $8,352,401.94. This trade represents a 52.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sara Bonstein sold 58,400 shares of Insmed stock in a transaction on Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at $7,546,758.35. The trade was a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 525,716 shares of company stock valued at $49,665,671. 3.00% of the stock is currently owned by company insiders.

Insmed Trading Up 0.0%

INSM stock traded up $0.05 during mid-day trading on Friday, hitting $127.80. 3,528,446 shares of the company were exchanged, compared to its average volume of 2,934,935. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $27.01 billion, a P/E ratio of -22.38 and a beta of 0.95. The business has a fifty day simple moving average of $103.62 and a 200-day simple moving average of $83.92. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $128.48.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. During the same period in the previous year, the business posted ($1.94) EPS. The company's revenue for the quarter was up 18.9% compared to the same quarter last year. On average, equities research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Citigroup upgraded shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. HC Wainwright boosted their target price on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Wells Fargo & Company upped their price objective on shares of Insmed from $130.00 to $140.00 and gave the stock an "overweight" rating in a research report on Tuesday. Jefferies Financial Group upped their price objective on shares of Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, UBS Group restated a "buy" rating and set a $133.00 price objective (up from $124.00) on shares of Insmed in a research report on Friday, August 8th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and an average target price of $129.57.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.